New drug duo aims to wipe out lingering breast cancer cells
NCT ID NCT07191717
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests two drugs, imlunestrant and abemaciclib, in 42 people with ER+ breast cancer who have tiny amounts of cancer DNA still in their blood after initial treatment. The goal is to see if the combination can clear these leftover cancer cells. Participants will take the drugs for up to 12 cycles and have blood samples and scans to track results.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
imlunestrant and abemaciclib
What this could lead to
If successful, this could lead to a new treatment option that clears remaining cancer cells from the blood, potentially reducing the risk of breast cancer recurrence.
What could go wrong
This is a small, early-phase trial with only 42 participants, so results may not apply to all patients. The drugs may cause side effects like fatigue or low blood cell counts, and the treatment may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE III BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••